期刊文献+

FK228阻断细胞生存信号通路诱导前列腺癌细胞凋亡 被引量:3

FK228 blocks cells survival signal pathways and induces apoptosis of prostate cancer DU145 cells
下载PDF
导出
摘要 目的:研究组蛋白去乙酰化酶(HDAC)抑制剂FK228诱导前列腺癌细胞系DU145凋亡的作用机制。方法:MTT比色法测定FK228抑制DU145细胞增殖及其对细胞的杀伤效应;瑞氏-姬姆萨染色观察细胞形态的变化;流式细胞术分析细胞周期的改变;蛋白印迹实验检测细胞内蛋白表达水平的变化。结果:FK228明显抑制DU145细胞体外增殖,并介导细胞死亡;12.5 ng/ml FK228作用细胞48 h后,细胞存活率降至63.7%;伴有细胞形态改变及细胞周期阻滞于G_0/G_1期;细胞内多种重要的激酶蛋白,包括EGFR、Her2、RM-1、Sic、Cdk4、Akt及凋亡抑制蛋白Survivin均发生了不同程度的降解,细胞内两条重要的生存信号通路Raf-MEK-ERK及PI3K/Akt被阻断,细胞发生凋亡。结论:FK228可以通过清除细胞内重要信号蛋白、阻断细胞生存信号通路来诱导DU145细胞发生凋亡。 Objective: To investigate the underlying mechanism of histone deacetylase (HDAC) inhibitor FK228-induced apoptosis of the prostate cancer cell line DU145. Methods: The inhibitory effect of FK228 on DU145 cell growth and its cytotoxicity were determined by MTT assay; cell cycle arrest was detected by flow cytometry assay; morphological change was observed by Giemsa staining; and defined kinase protein levels were determined by Western blot analysis. Resuits: FK228 obviously inhibited DU145 cells growth , arrested cell cycle at Go/G, phase, induced ceils morphological changes and degraded several kinase proteins, including EGFR, Her2, Raf-1, Src, Cdk4 and IAP member Survivin. The degradation of these kinases blocked Raf-Mek-Erk and PI3K/Akt survival signal pathways, inducing apoptosis. Conclusion: FK228 may induce DU145 cell apoptosis through depletion of multiple kinase proteins and blockade of survival signal pathways of DU145 cells.
出处 《中国肿瘤生物治疗杂志》 CAS CSCD 2006年第2期83-87,共5页 Chinese Journal of Cancer Biotherapy
基金 国家自然科学基金重点项目资助课题(30330620)
关键词 组蛋白去乙酰化酶 FK228 热休克蛋白90 细胞凋亡 前列腺癌 histone deacetylase FK228 heat shock protein 90 apoptosis prostate cancer
  • 相关文献

参考文献16

  • 1Johnstone RW. Histone deacetylase inhibitors: Novel drugs for the treatment of cancer[ J]. Nat Rev Drug Discov, 2002, 1(4) : 287- 299.
  • 2Marks PA, Richon VM, Rifkind RA. Histone deacetylase inhibitors: Inducers of differentiation or apoptosis of transformed cells[J]. J Natl Cancer 1nst, 2000, 92(15) : 1210-1216.
  • 3Kovacs JJ, Murphy PJ, Gaillard S, et al. HDAC6 regulates HSP90 acetylation and chaperone-dependent activation of glucocorticoid receptor [ J ]. Mol Cell, 2005, 18 (5) : 601-607.
  • 4Grossmann ME, Huang H, Tindall DJ. Androgen receptor signaling in androgen-refractory prostate cancer [ J ]. J Natl Cancer 1nst, 2001, 93(22) : 1687-1697.
  • 5Culig Z, Steiner H, Bartsch G, et al. Mechanisms of endocrine therapy-responsive and-unresponsive prostate tumors[ J ]. Endocr Relat Cancer, 2005, 12(2) : 229-244.
  • 6Marks PA, Millery T, Richony VM. Histone deacetylases [ J]. Curt Opin Pharmacol, 2003, 3(4) : 344-351.
  • 7Byrd JC, Marcueei G, Parthun MR, et al. A phase 1 and pharmacodynamic study of depsipeptide ( FK228 ) in chronic lymphocytic leukemia and acute myeloid leukemia[ J ]. Blood, 2005, 105 (3) :959-967.
  • 8Bali P, Pranpat M, Bradner J, et al. Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: A novel basis for antileukemia activity of histone deacetylase inhibitors[ J ]. J Biol Chem, 2005, 280 (29) : 26729-26734.
  • 9Furumai R, Matsuyama A, Kobashi N, et al. FK228 (depsipeptide) as a natural prodrug that inhibits class Ⅰ histone deacetylases [ J ]. Cancer Res, 2002, 62 ( 17 ) : 4916-4921.
  • 10Gui CY, Ngo L, Xu WS, et al. Histone deacetylase (HDAC) inhibitor activation of p21^WAF1 involves changes in promoter-associated proteins, including HDAC1 [J]. Proc Natl Acad Sci USA, 2004. 101(5) : 1241-1246.

同被引文献18

  • 1张亚鹏,朱伟明,顾谦群,朱天骄.源于海洋真菌抗肿瘤活性物质的研究进展[J].中国海洋药物,2006,25(1):54-58. 被引量:16
  • 2李薇,王冠军,崔久嵬,陈晓锋,张学敏.丁酸钠诱导NB4细胞凋亡的蛋白质组学研究[J].中华血液学杂志,2006,27(7):436-440. 被引量:4
  • 3温星桥,李小娟,罗云,王林,周祥福,蔡育彬,温机灵,高新.生育酚结合蛋白通过磷酸肌醇3激酶途径抑制前列腺癌的生长[J].中山大学学报(医学科学版),2007,28(4):367-372. 被引量:4
  • 4Furumai T, Igarashi Y, Higushi H, et al. Kosinostatin, a quinocycline antibiotic with antitumor activily from Micromonospora sp. TP-A0468. J Antibiot ( Tokyo), 2002, 55 (2) : 128-133.
  • 5Schroder FH. Progress in understanding androgen-independent prostate cancer(AIPC) : a review of potential endocrinemediated mechanisms. Eur Urol, 2008, 53 (6) : 1129-1137.
  • 6Rege YD, Rangnekar VM. Molecular therapy intervention prospects in prostate cancer. Curr Pharm Des, 2004, 10 (5) :523-530.
  • 7Acharya MR,Sparreboom A,Venitz J,et al.Rational development of histone deacetylase inhibitors as anticancer agents.Mol Pharmacol,2005,68:917-932.
  • 8Saito A,Yamashita T,Mariko Y,et al.A synthetic inhibitor of histone deacetylase,MS-27-275,with marked in vivo antitumor activity against human tumors.Proc Natl Acad Sci U S A,1999,96:4592-4597.
  • 9Jaboin J,Wild J,Hamidi H,et al.MS-27-275,an inhibitor of histone deacetylase,has marked in vitro and in vivo antitumor activity against pediatric solid tumors.Cancer Res,2002,62:6108-6115.
  • 10Gojo I,Jiemjit A,Trepel JB,et al.Phase 1 and pharmacologic study of MS-275,a histone deacetylase inhibitor,in adults with refractory and relapsed acute leukemias.Blood,2007,109:2781-2790.

引证文献3

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部